ES2042520T3 - Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. - Google Patents

Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.

Info

Publication number
ES2042520T3
ES2042520T3 ES87107979T ES87107979T ES2042520T3 ES 2042520 T3 ES2042520 T3 ES 2042520T3 ES 87107979 T ES87107979 T ES 87107979T ES 87107979 T ES87107979 T ES 87107979T ES 2042520 T3 ES2042520 T3 ES 2042520T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
methyl ester
preparation
compositions containing
therapeutic applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87107979T
Other languages
English (en)
Inventor
Paolo Chiesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT20737/86A external-priority patent/IT1190342B/it
Priority claimed from IT19221/87A external-priority patent/IT1203321B/it
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2042520T3 publication Critical patent/ES2042520T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

COMPOSICIONES FARMACEUTICAS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON Y SINDROMES NEURALGICOS CONECTADOS CON ESTA, CONTENIENDO COMO PRINCIPIO ACTIVO EL ESTER METIL LEVODOPA COMBINADO OPCIONALMENTE CON OTROS PRINCIPIOS ACTIVOS SELECCIONADOS DE FARMACOS DOPAMINERGICOS,, ANTICOLINERGICO, ANTIDEPRESIVOS E INHIBIDORES DE MONOAMINOXIDASA Y CARBOXILASA.
ES87107979T 1986-06-10 1987-06-02 Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. Expired - Lifetime ES2042520T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT20737/86A IT1190342B (it) 1986-06-10 1986-06-10 Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche
IT19221/87A IT1203321B (it) 1987-01-30 1987-01-30 Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche

Publications (1)

Publication Number Publication Date
ES2042520T3 true ES2042520T3 (es) 1993-12-16

Family

ID=26327098

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87107979T Expired - Lifetime ES2042520T3 (es) 1986-06-10 1987-06-02 Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.

Country Status (13)

Country Link
US (2) US4826875A (es)
EP (1) EP0252290B1 (es)
JP (1) JP2572768B2 (es)
KR (2) KR880000092A (es)
AT (1) ATE76747T1 (es)
AU (1) AU605154B2 (es)
CA (1) CA1303509C (es)
DE (2) DE3779500T2 (es)
ES (1) ES2042520T3 (es)
GR (1) GR880300058T1 (es)
HU (1) HUT43952A (es)
NZ (1) NZ220631A (es)
PT (1) PT85055B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
DE4325435A1 (de) * 1993-07-29 1995-02-02 Basf Ag Neue Wirkstoffkombination
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
EP0814789B2 (en) * 1995-03-02 2008-01-09 R.P. Scherer Technologies, Inc. Pharmaceutical compositions comprising monoamine oxidase b inhibitors
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
NZ309980A (en) 1995-06-07 2001-06-29 Noven Pharma Transdermal composition containing a blend of one or more polymers, one or more drugs that has a low molecular weight and is liquid at room temperature
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
ATE292619T1 (de) 1996-12-18 2005-04-15 Teva Pharma Aminoindanderivate
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
DE69902520T2 (de) 1998-03-16 2003-04-10 Somerset Pharmaceuticals Inc Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
CN1329487A (zh) 1998-11-10 2002-01-02 特瓦制药工业有限公司 包含l－多巴乙酯的可分散组合物
AU764844B2 (en) 1998-11-10 2003-09-04 Teva Pharmaceutical Industries Ltd. Process for manufacture of L-DOPA ethyl ester
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CA2523567A1 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
WO2005023185A2 (en) * 2003-08-29 2005-03-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
MXPA06004327A (es) * 2003-10-20 2007-01-26 Teva Pharma Composiciones y forma de dosificacion para el efecto retardado de levodopa.
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7342131B2 (en) * 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
PT1959948E (pt) * 2005-12-05 2012-09-12 Xenoport Inc Mesilato de pró-fármaco de levodopa, suas composições e suas utilizações
BRPI0620659A2 (pt) * 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
WO2007093450A2 (en) * 2006-02-17 2007-08-23 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
TW200843731A (en) * 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CA2676139C (en) 2007-02-06 2016-04-26 Origin Biomed Inc. Composition comprising terpene compounds and methods for inhibiting nerve transmission
US20090143388A1 (en) * 2007-08-29 2009-06-04 Mohanakumar Kochupurackal Para Treatment of brain disorders
CN101283965B (zh) * 2007-10-26 2010-06-16 南京长澳医药科技有限公司 一种含左旋多巴甲酯的制剂及制备方法
MX2010007207A (es) 2007-12-28 2011-02-23 Impax Laboratories Inc Formulaciones de liberacion controlada de levodopa y usos de las mismas.
JP2011530543A (ja) 2008-08-13 2011-12-22 ニューロクエスト インク 感覚欠損を治療するための組成物および方法
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8286311B2 (en) 2008-10-31 2012-10-16 Jisook Paik Buckle
US20120128654A1 (en) * 2009-04-23 2012-05-24 University Of Cincinnati Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma
SG10201709016RA (en) 2009-05-19 2017-11-29 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
RS57047B1 (sr) 2010-11-15 2018-05-31 Neuroderm Ltd Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste
EP2648716A4 (en) * 2010-12-10 2015-05-20 Synagile Corp PRODUCT COMPOSITIONS OF SUVUTABLY PERFUSABLE LÉVODOPA
EP3456315A1 (en) 2012-06-05 2019-03-20 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
US10188617B2 (en) 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
JP6442475B2 (ja) 2013-03-15 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
PL3054929T3 (pl) * 2013-10-07 2021-05-31 Impax Laboratories, Llc Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
RS65060B1 (sr) 2014-03-13 2024-02-29 Neuroderm Ltd Sastavi inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN107847722B (zh) 2015-05-06 2021-05-18 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
WO2019166322A1 (en) 2018-03-02 2019-09-06 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787581A (en) * 1970-03-24 1974-01-22 M Sandler Pharmaceutical compositions and methods of treatment
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
AU605154B2 (en) 1991-01-10
KR890001533A (ko) 1989-03-27
HUT43952A (en) 1988-01-28
KR950002150B1 (ko) 1995-03-14
DE252290T1 (de) 1988-06-09
PT85055A (pt) 1988-07-01
US4826875A (en) 1989-05-02
JPS6327428A (ja) 1988-02-05
CA1303509C (en) 1992-06-16
DE3779500D1 (de) 1992-07-09
NZ220631A (en) 1990-12-21
JP2572768B2 (ja) 1997-01-16
PT85055B (pt) 1994-10-31
US5017607A (en) 1991-05-21
EP0252290B1 (en) 1992-06-03
AU7405387A (en) 1987-12-17
EP0252290A3 (en) 1990-01-24
KR880000092A (ko) 1988-03-23
DE3779500T2 (de) 1993-01-21
EP0252290A2 (en) 1988-01-13
GR880300058T1 (en) 1988-10-18
ATE76747T1 (de) 1992-06-15

Similar Documents

Publication Publication Date Title
ES2042520T3 (es) Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
DE3686483D1 (de) Arzneimittel.
DE3382641T2 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
NO306677B1 (no) Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament
NO172389C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazoler
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
DE69231298T2 (de) Substituierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen und Anwendungsmethoden
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
SE8404065D0 (sv) Novel biologically active compounds
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
MC2025A1 (fr) Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
DK561589A (da) Flydende oralt farmaceutisk praeparat
ES2106025T3 (es) Analogos de gangliosidos semisinteticos.
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
ES2039255T3 (es) Utilizacion de n-((1-etil-2-pirrolidinil)metil)-2-metoxi-5-sulfamoil-benzamida en el tratamiento de la esterilidad.
TH14574A (th) สารผสมทางเภสัชกรรม
UA30143C2 (uk) Лікувальний препарат для профілактики та лікування інфекційних та запальних захворювань
ITMI911048A0 (it) Nuove composizioni farmaceutiche per il trattamento del morbo di parkinson
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
TH19526A (th) วิธีการและสารผสมสำหรับรักษาโรคตับอักเสบชนิดออโตอิมมูน

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 252290

Country of ref document: ES